These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 23943313)
21. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. Arabi L; Badiee A; Mosaffa F; Jaafari MR J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722 [TBL] [Abstract][Full Text] [Related]
22. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506 [TBL] [Abstract][Full Text] [Related]
23. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates. Hebert C; Norris K; Sauk JJ J Drug Target; 2003 Feb; 11(2):101-7. PubMed ID: 12881196 [TBL] [Abstract][Full Text] [Related]
24. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates. Shiah JG; Sun Y; Kopecková P; Peterson CM; Straight RC; Kopecek J J Control Release; 2001 Jul; 74(1-3):249-53. PubMed ID: 11489502 [TBL] [Abstract][Full Text] [Related]
25. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252 [TBL] [Abstract][Full Text] [Related]
26. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance. Wang C; Wei X; Shao G Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008 [TBL] [Abstract][Full Text] [Related]
27. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models. Jia D; Yang Y; Yuan F; Fan Q; Wang F; Huang Y; Song H; Hu P; Wang R; Li G; Liu R; Li J Int J Pharm; 2020 Aug; 586():119541. PubMed ID: 32544521 [TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate. Yang T; Xu L; Li B; Li W; Ma X; Fan L; Lee RJ; Xu C; Xiang G Int J Nanomedicine; 2017; 12():2505-2515. PubMed ID: 28408821 [TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice. Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425 [TBL] [Abstract][Full Text] [Related]
30. Tumor targeting using anti-her2 immunoliposomes. Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods. Sinkule JA; Rosen ST; Radosevich JA Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554 [TBL] [Abstract][Full Text] [Related]
32. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847 [TBL] [Abstract][Full Text] [Related]
34. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Stan AC; Radu DL; Casares S; Bona CA; Brumeanu TD Cancer Res; 1999 Jan; 59(1):115-21. PubMed ID: 9892195 [TBL] [Abstract][Full Text] [Related]
35. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565 [TBL] [Abstract][Full Text] [Related]
36. CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells. Jiang S; Wang X; Zhang Z; Sun L; Pu Y; Yao H; Li J; Liu Y; Zhang Y; Zhang W Int J Nanomedicine; 2016; 11():5505-5518. PubMed ID: 27843311 [TBL] [Abstract][Full Text] [Related]
37. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482 [TBL] [Abstract][Full Text] [Related]
38. Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer. Han NN; Li X; Tao L; Zhou Q Biochem Biophys Res Commun; 2018 Mar; 498(1):178-185. PubMed ID: 29317204 [TBL] [Abstract][Full Text] [Related]
39. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209 [TBL] [Abstract][Full Text] [Related]